Delving into the Latest Updates on ONO-2020 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ONO 2020, ONO2020

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System Diseases

Active Indication

Alzheimer Disease

Inactive Indication-

Originator Organization

Ono Pharmaceutical Co., Ltd.

Active Organization

Ono Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.

Start Date24 Apr 2025

Sponsor / Collaborator

Ono Pharmaceutical Co., Ltd.

NCT05507515

/ CompletedPhase 1

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Five-part Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of ONO-2020 in Healthy Participants

The purpose of this FIH study is to evaluate the safety, tolerability and pharmacokinetics of ONO-2020 in healthy adult participants. This FIH study consists of five parts (Parts A-E) to study single or multiple doses of ONO-2020 in healthy participants, including elderly and Japanese participants, as well as the food effect on the PK of ONO-2020. These data will support the clinical development program and help inform dose selection in future studies.

Start Date29 Jul 2022

Sponsor / Collaborator

Ono Pharmaceutical Co., Ltd.

100 Clinical Results associated with ONO-2020

Login to view more data

100 Translational Medicine associated with ONO-2020

Login to view more data

100 Patents (Medical) associated with ONO-2020

Login to view more data

100 Deals associated with ONO-2020

Login to view more data